Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasiaROEHRBORN, Claus G; LEE, Michael; MEEHAN, Alan et al.Urology (Ridgewood, NJ). 2003, Vol 62, Num 5, pp 894-899, issn 0090-4295, 6 p.Article

The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: Results of a 4-year placebo controlled trialMATSUMOTO, Alvin M; TENOVER, Lisa; ZHANG, Gang K et al.The Journal of urology. 2002, Vol 167, Num 5, pp 2105-2108, issn 0022-5347Article

Urinary retention in patients with BPH treated with finasteride or placebo over 4 years : Characterization of patients and ultimate outcomesROEHRBORN, C. G; BRUSKEWITZ, R; HOLTGREWE, H. L et al.European urology. 2000, Vol 37, Num 5, pp 528-536, issn 0302-2838Article

Economic analysis of finasteride : A model-based approach using data from the Proscar® Long-Term Efficacy and safety studyALBERTSEN, P. C; PELLISSIER, J. M; LOWE, F. C et al.Clinical therapeutics. 1999, Vol 21, Num 6, pp 1006-1024, issn 0149-2918Article

Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomesROEHRBORN, Claus G; MCCONNELL, John D; SALTZMAN, Brian et al.European urology. 2002, Vol 42, Num 1, pp 1-6, issn 0302-2838Article

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?YANG, X. J; LECKSELL, K; ROUSE, S et al.Urology (Ridgewood, NJ). 1999, Vol 53, Num 4, pp 696-700, issn 0090-4295Article

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasiaROEHRBORN, C. G; MCCONNELL, J. D; COOK, T. J et al.Urology (Ridgewood, NJ). 1999, Vol 53, Num 3, pp 473-480, issn 0090-4295Article

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate : Results of a four-year, randomized trial comparing finasteride versus placeboROEHRBORN, C. G; BOYLE, P; WANG, D et al.Urology (Ridgewood, NJ). 1999, Vol 54, Num 4, pp 662-669, issn 0090-4295Article

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasterideKAPLAN, Steven; GARVIN, Dennis; LEE, Michael et al.Urology (Ridgewood, NJ). 2000, Vol 56, Num 4, pp 610-616, issn 0090-4295Article

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasiaBRUSKEWITZ, R; GIRMAN, C. J; WANG, D. Z et al.Urology (Ridgewood, NJ). 1999, Vol 54, Num 4, pp 670-678, issn 0090-4295Article